Hemostemix Company Description

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada.

Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function.

The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

Hemostemix Inc. is headquartered in Calgary, Canada.